An initiative of IBA Proton Therapy
Campus your proton
therapy community
  • Resource center
  • Training
  • Events
  • About
  • Log in
  • Resource center
  • Training
  • Events
  • About
  • Log in
An initiative of IBA Proton Therapy

Your results for

Filter by

Filter by
Results

Filter by

Content type
  • Event - Do not use (0)
  • Podcast (0)
  • Publications (98)
  • Training (0)
  • User case (3)
  • User meeting (0)
  • Webinar (1)
  • White paper (3)
Key content topics
Key audience
  • Newcomers (0)
Top cancer treatments
  • Brain and CNS (88)
  • Breast (59)
  • Gastro-intestinal (125)
  • Genito-urinary (51)
  • Gynecological (7)
  • Head and neck (133)
  • (-) Hodgkin and Non-Hodgkin lymphoma (16)
  • Ocular (12)
  • Pediatric (100)
  • Reirradiation (12)
  • Sarcomas (18)
  • (-) Thoracic (91)
  • Reset filters
  • (-) Hodgkin and Non-Hodgkin lymphoma
  • (-) Thoracic

Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.

28/03/2024
/ Publications
/
IMPT
IMRT
Toxicity

This study reported the incidence of lymphopenia in 271 stage III NSCLC patients treated with IMPT (n=71) vs IMRT (n=200) and concurrent chemotherapy. The...

Long-term survival outcomes and quality of life of image-guided proton therapy for operable stage I non-small cell lung cancer: A phase 2 study.

06/05/2024
/ Publications
/
Survival
Quality of life
Toxicity

This study from Japan reported clinical outcomes of 43 patient with operable stage IA or IB NSCLC treated with a dose of 66 GyRBE in 10 fractions for peripheral...

Prospective study investigating hypofractionated proton beam therapy in patients with inoperable early stage non-small cell lung cancer.

06/05/2024
/ Publications
/
Toxicity

This study by the Samsung group, Korea, reported clinical outcomes of 27 patients with inoperable early stage NSCLC treated by protons to a total dose of 64...

FLASH radiotherapy for the treatment of symptomatic bone metastases in the thorax (FAST-02): protocol for a prospective study of a novel radiotherapy approach.

06/05/2024
/ Publications
/
FLASH Therapy

This is a trial protocol of FAST-02. This trial includes 10 patients with 1-3 painful bone metastases in the thorax, excluding bone metastases in the spine...

A bibliometric analysis of cardiotoxicity in cancer radiotherapy.

06/05/2024
/ Publications
/
Quality of life
Survival

Radiation induced heart disease (RIHD) significantly impacts the long-term survival and quality of life of cancer survivors as one of the most devastating...

Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives.

14/02/2021
/ Publications
/
Reirradiation

This review examines the evolving role of PBT in the treatment of thoracic malignancies and evaluates the data supporting its use. Clinical outcomes data of PBT...

Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer.

14/03/2021
/ Publications
/
Toxicity

This study retrospectively reviewed 53 patients who received salvage PBT for locoregionally recurrent NSCLC. With a median follow-up time of 15.0 months, 26...

Proton beam radiotherapy for patients with early-stage and advanced lung cancer: a narrative review with contemporary clinical recommendations.

14/02/2021
/ Publications

A review article examined data available of proton radiation for early-stage, advanced-stage and recurrent NSCLC, as well as protons in post-operative...

Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer.

14/09/2021
/ Publications
/
IMRT
Toxicity

This study retrospectively evaluated 136 postoperative radiotherapy (PORT) patients (61 PBT, 75 IMRT). Median OS was 76 and 46 months for PBT and IMRT with...

Long-term outcomes of high-dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall-cell lung cancer.

14/05/2021
/ Publications
/
Dosimetry
Toxicity

This study reported outcomes of 45 patients with stage III NSCLC treated with PBT of 74 GyE and concurrent chemotherapy. With a median follow-up time of 42.1...

Pagination

  • Previous page ‹
    • Page 7
    • Current page 8
    • Page 9
  • Next page ›
Campus
Subscribe to our newsletter
Follow us on
  • Facebook
  • Linkedin
  • Twitter
  • Youtube
Contact us
  • About Campus
  • Resources
  • Training
  • Connect
  • IBA Worldwide
  • Back to IBA Proton Therapy
Life Science
  • Legal
  • Terms of Use
  • Privacy policy
  • Cookies policy
  • Manage cookies
  • Code of conduct

Cookies policy

If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.

Manage your cookie preferences

Respect for your privacy is still a priority for us at IBA.

Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.

Accept all cookies
Adapt my preferences
Cookies policies